Parkman Healthcare Partners’s Mineralys Therapeutics MLYS Stock Holding History

Parkman Healthcare Partners’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3M	Buy	380,354 +217	+0.1%	+$5.95K	1.05%	39
2026 Q1	$10.3M	Sell	380,137 -30,112	-7%	-$883K	1.06%	33
2025 Q4	$14.9M	Sell	410,249 -45,274	-10%	-$1.82M	1.42%	23
2025 Q3	$17.3M	Sell	455,523 -8,078	-2%	-$175K	1.8%	17
2025 Q2	$6.27M	Buy	463,601 +169,673	+58%	+$2.46M	0.72%	52
2025 Q1	$4.67M	Buy	+293,928	New	+$3.38M	0.55%	52
2023 Q3	–	Sell	-11,658	Closed	-$199K	–	108
2023 Q2	$199K	Buy	11,658 +1,658	+17%	+$24.8K	0.03%	94
2023 Q1	$157K	Buy	+10,000	New	+$168K	0.03%	83

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Parkman Healthcare Partners's MLYS Position: Q2 2026 in Review

Parkman Healthcare Partners increased its Mineralys Therapeutics (MLYS) stake by 0.06% in Q2 2026, buying an estimated $5.95K and bringing the position to 380,354 shares worth $10.3M. The position accounts for 1.05% of the portfolio, ranked #39.

Parkman Healthcare Partners first reported a position in MLYS in Q1 2023 and has held it in 8 quarters since. The position peaked at $17.3M in Q3 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Parkman Healthcare Partners held 380,354 shares of Mineralys Therapeutics worth $10.3M as of Q2 2026.
Parkman Healthcare Partners bought 217 Mineralys Therapeutics shares in Q2 2026, an estimated $5.95K.
Mineralys Therapeutics made up 1.05% of Parkman Healthcare Partners's portfolio in Q2 2026, its #39 holding.
Parkman Healthcare Partners first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 8 quarters since.
Parkman Healthcare Partners's Mineralys Therapeutics position peaked at $17.3M in Q3 2025.
225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.